CLB — Core Laboratories NV Share Price
- $1.21bn
- $1.38bn
- $470.25m
- 92
- 16
- 42
- 50
Momentum
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 27.2 | ||
PEG Ratio (f) | 0.61 | ||
EPS Growth (f) | 79.52% | ||
Dividend Yield (f) | 0.15% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 7.48 | ||
Price to Tang. Book | 22.28 | ||
Price to Free Cashflow | 58.17 | ||
Price to Sales | 2.54 | ||
EV to EBITDA | 27.01 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 6.85% | ||
Return on Equity | 6.41% | ||
Operating Margin | 6.97% |
Financial Summary
Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 647.82 | 700.85 | 668.21 | 487.27 | 470.25 | 510.8 | 581.24 | -4.44% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +24.86 | -3.43 | +16.94 | n/a | n/a | +80.38 | +78.8 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples. It provides analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry. The Production Enhancement segment includes products and services relating to reservoir well completions, perforations, stimulations and production. It provides integrated diagnostic services to evaluate the effectiveness of well completions. The Reservoir Management segment combines and integrates information from reservoir description and production enhancement services to increase production and recovery of oil and gas from its clients' reservoirs.
Directors
- Lawrence Bruno CSU (61)
- Christopher Hill CFO (51)
- Mark Elvig GCN
- Martha Carnes LED (61)
- Gregory Barnett IND (59)
- Harvey Klingensmith IND (68)
- Michael Straughen IND (71)
- Monique Van Dijken Eeuwijk IND (51)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- July 8th, 1994
- Public Since
- July 10th, 1998
- No. of Shareholders
- 217
- No. of Employees
- 3,700
- Sector
- Oil & Gas Related Equipment and Services
- Industry
- Energy
- Exchange
New York Stock Exchange
- Shares in Issue
- 46,307,537

- Address
- Van Heuven Goedhartlaan 7 B, AMSTELVEEN, 1181 LE
- Web
- https://www.corelab.com/
- Phone
- +31 204203191
- Auditors
- KPMG LLP
Upcoming Events for CLB
Q3 2022 Core Laboratories NV Earnings Release
Similar to CLB
Antero Midstream
New York Stock Exchange
Archrock
New York Stock Exchange
Ardmore Shipping
New York Stock Exchange
Aris Water Solutions
New York Stock Exchange
Borr Drilling
New York Stock Exchange
FAQ
As of Today at 07:05 UTC, shares in Core Laboratories NV are trading at $26.15. This share price information is delayed by 15 minutes.
Shares in Core Laboratories NV last closed at $26.15 and the price had moved by -31.27% over the past 365 days. In terms of relative price strength the Core Laboratories NV share price has underperformed the S&P500 Index by -27.52% over the past year.
The overall consensus recommendation for Core Laboratories NV is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Core Laboratories NV dividend yield is 0.15% based on the trailing twelve month period.
Last year, Core Laboratories NV paid a total dividend of $0.04, and it currently has a trailing dividend yield of 0.15%. We do not have any data on when Core Laboratories NV is to next pay dividends.
We do not have data on when Core Laboratories NV is to next pay dividends. The historic dividend yield on Core Laboratories NV shares is currently 0.15%.
To buy shares in Core Laboratories NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $26.15, shares in Core Laboratories NV had a market capitalisation of $1.21bn.
Here are the trading details for Core Laboratories NV:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: CLB
Based on an overall assessment of its quality, value and momentum Core Laboratories NV is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Core Laboratories NV is $27.83. That is 6.42% above the last closing price of $26.15.
Analysts covering Core Laboratories NV currently have a consensus Earnings Per Share (EPS) forecast of $0.73 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Core Laboratories NV. Over the past six months, its share price has outperformed the S&P500 Index by +26.75%.
As of the last closing price of $26.15, shares in Core Laboratories NV were trading -4.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Core Laboratories NV PE ratio based on its reported earnings over the past 12 months is 27.2. The shares last closed at $26.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Core Laboratories NV's management team is headed by:
- Lawrence Bruno - CSU
- Christopher Hill - CFO
- Mark Elvig - GCN
- Martha Carnes - LED
- Gregory Barnett - IND
- Harvey Klingensmith - IND
- Michael Straughen - IND
- Monique Van Dijken Eeuwijk - IND